{"ticker": {"uuid": "72fd4e45-5dba-4b3b-a5c9-371f2e1ca798", "symbol": "INVA", "name": "Innoviva Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Innoviva stock trades down to $22.49 as Western Thoracic conference focus draws attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOemJlbV9MU2JvblA5YUFWWGVoSnpPWXJOZGhtUWI0ZDlMQTJRVEhHSHRUb3lJWElUcnZxTm9LZkpFSlE4Tm1DOS1YdHRsY1FSYTAzaW5TYzJIVUFxeGNTQVZ6SGhfM0lybERUcXRCSk1UNGpZYmJhZy02RjVFTUI3X2xSX3hmZURuRGU2Wm1UQmhmY1R3UDIwdg?oc=5", "source_name": "Traders Union", "published_at": "2026-06-22T11:28:08+00:00", "published_display": "22 Jun 2026 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) Stock Could Be 61% Below Fair Value After XACDURO Deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T23:41:38+00:00", "published_display": "20 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will XACDURO Licensing Deal With Dr. Reddy\u2019s Reshape Innoviva\u2019s (INVA) Infectious Disease Strategy?", "summary": "Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., recently entered an exclusive distribution and licensing agreement with Dr. Reddy\u2019s Laboratories for XACDURO\u00ae across various international regions. This deal helps expand XACDURO\u00ae's global reach and offers Innoviva ", "url": "https://www.sahmcapital.com/news/content/will-xacduro-licensing-deal-with-dr-reddys-reshape-innovivas-inva-infectious-disease-strategy-2026-06-19", "source_name": "Sahm", "published_at": "2026-06-19T21:09:36", "published_display": "19 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nortiva Bio Launches to Develop Long-Acting Oral Medicines", "summary": "Nortiva Bio, a clinical-stage biopharmaceutical company and wholly-owned subsidiary of Innoviva, Inc., has officially launched to develop long-acting oral medicines. The company utilizes its proprietary LYNX\u2122 drug delivery platform, which can transform daily pills into once-month", "url": "https://www.businesswire.com/news/home/20260618487727/en/Nortiva-Bio-Launches-to-Develop-Long-Acting-Oral-Medicines", "source_name": "Business Wire", "published_at": "2026-06-19T08:39:18", "published_display": "19 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Innoviva Inc (INVA), detailing its current earnings forecast score, average price target from analysts, and a breakdown of analyst ratings. It also includes expected revenue for the next quarter, past and future EPS performance, and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T21:09:36", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva spins out Nortiva Bio to make pills last up to a month", "summary": "Innoviva, Inc. has officially launched Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines using its proprietary LYNX\u2122 drug delivery platform. This platform aims to transform daily pills into single-dose therapies lasting up to", "url": "https://www.stocktitan.net/news/INVA/nortiva-bio-launches-to-develop-long-acting-oral-7zyvymcas4kb.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:40:13", "published_display": "18 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Innoviva Inc (INVA) demonstrates robust financial health, ranking 22nd out of 157 in the Pharmaceuticals industry with a financial score of 8.98. The company reported a 10.56% year-over-year increase in quarterly revenue to $97.99 million and a significant 500.56% year-over-year ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:18", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE5hZkI4ZmFsWXFaWFFUSVlIalJ4Zy1UV0thRERxQU5ZTi1RY0o3dVllcmFGUHAzUlBobTVtZGtWemJUblc2d0lqeWIzaEd3MkJrY0tVWk9yTERaaTVkWmdVYlljOXd0bzd1UW9sQ0k3WWhPTHZJdVdV?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:53:36+00:00", "published_display": "17 Jun 2026 21:53", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE0yWUdDMGNXaTNkeXgtQkttajlRNlF3eExmbUZ1MkFYMHR0bzkxNE9FanNxNHZvY2lPbzNkcFUwb1hXZmFEVUxpM3paZWZTcmVMZXdkd0dyamxYVHVIRkVMWWVJUGs5elE1bThDeUxHaTQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:47:04+00:00", "published_display": "17 Jun 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Innoviva Inc (INVA), focusing on business segments and regional contributions. It notes that relevant data for recent fiscal quarters (FY2025Q1, Q2, Q4) and FY2024 has not yet been disclosed by the company. However, it does show a Uni", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:04", "published_display": "17 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Innoviva Inc's (INVA) historical dividend payouts and stock splits. It states that no dividend data is available for the past five years and no stock split data is found. The article also includes current stock performance metrics for INVA.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:03", "published_display": "17 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Innoviva Inc (INVA), listing its major shareholders and their respective proportions. It also categorizes shareholders by type, such as investment advisors and hedge funds, and provides a historical overview of institutional share", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T18:11:03", "published_display": "17 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Specialty Therapeutics inks distribution and licensing agreement with Dr. Reddy\u2019s", "summary": "Innoviva Specialty Therapeutics has partnered with Dr. Reddy\u2019s Laboratories through an exclusive distribution and licensing agreement. This collaboration aims to develop and commercialize XACDURO\u00ae for the treatment of severe Acinetobacter baumannii-calcoaceticus complex infection", "url": "https://www.biospectrumindia.com/news/16/27981/innoviva-specialty-therapeutics-inks-distribution-and-licensing-agreement-with-dr-reddys-.html", "source_name": "BioSpectrum India", "published_at": "2026-06-17T11:11:03", "published_display": "17 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy\u2019s for XACDURO", "summary": "Innoviva Specialty Therapeutics has partnered with Dr. Reddy\u2019s Laboratories for the distribution and licensing of XACDURO in select international markets including South and Central America, the Caribbean, Russia, and CIS countries. This agreement aims to expand access to XACDURO", "url": "https://www.businesswire.com/news/home/20260616536715/en/Innoviva-Specialty-Therapeutics-Announces-Distribution-and-Licensing-Agreement-with-Dr.-Reddys-for-XACDURO-in-Select-International-Markets", "source_name": "Business Wire", "published_at": "2026-06-17T08:39:18", "published_display": "17 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy\u2019s for XACDURO\u00ae in Select International Markets", "summary": "Innoviva Specialty Therapeutics has partnered with Dr. Reddy's Laboratories to distribute and commercialize the pneumonia drug XACDURO in Latin America, the Caribbean, Russia, and CIS countries. This agreement aims to expand access to XACDURO, an antibiotic for hospital-acquired ", "url": "https://www.stocktitan.net/news/INVA/innoviva-specialty-therapeutics-announces-distribution-and-licensing-uqmj82r0xass.html", "source_name": "Stock Titan", "published_at": "2026-06-17T07:40:03", "published_display": "17 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva unit signs distribution deal with Dr. Reddy\u2019s By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQanIxYU9LdUNTREZQSHc4U2VxTXN3TndpelFScDZWRF9oX3hhVXk3RFF4Yy1nc08zQmdRWm9yOWZ0dFNLVXpXQVlRN1VHNU44bkRPMTFNUmZHQUd6d1FnUlgyVUItMjZ5WGs3QWlraU1GQXpCdDgxNEQ5Vzc1RmljeFBPVHR3TUVYd1FDaW5WSW0zZTZHZllRbVRSbGZJbmV5TW1fS3FjV1dRY1JvVlhXcmZBWQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T14:08:00+00:00", "published_display": "16 Jun 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva partners with Dr. Reddy's for XACDURO licensing", "summary": "Innoviva Specialty Therapeutics has entered an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for its antibiotic XACDURO. Dr. Reddy's will handle the development and commercialization of the drug in South America, Central America, the Caribbean, and ", "url": "https://grafa.com/en/news/united-states/innoviva-dr-reddys-xacduro-licensing-agreement", "source_name": "grafa.com", "published_at": "2026-06-16T14:09:28", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva' Specialty Therapeutics Unit Signs Licensing Deal With Dr. Reddy's for Xacduro", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/innoviva-apos-specialty-therapeutics-unit-122119947.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:21:19+00:00", "published_display": "16 Jun 2026 12:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva unit signs distribution deal with Dr. Reddy\u2019s", "summary": "Innoviva Specialty Therapeutics has signed an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd. for its antibiotic XACDURO in South and Central America, the Caribbean, Russia, and CIS countries. Innoviva Inc. (NASDAQ:INVA) is set to receive an upfr", "url": "https://m.uk.investing.com/news/stock-market-news/innoviva-unit-signs-distribution-deal-with-dr-reddys-93CH-4730598?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-16T13:10:29", "published_display": "16 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the INVA Inflection", "summary": "This article analyzes Innoviva Inc. (NASDAQ: INVA) with a neutral near and mid-term outlook but a positive long-term bias. It highlights a strong risk-reward short setup and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, eac", "url": "https://news.stocktradersdaily.com/news_release/149/Responsive_Playbooks_and_the_INVA_Inflection_061626033802_1781595482.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T03:38:00", "published_display": "16 Jun 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary", "summary": "Innoviva (INVA) presented at the 47th Annual Goldman Sachs Global Healthcare Conference, highlighting its diversified business model comprising resilient royalty streams, a rapidly growing specialty therapeutics business (IST), and strategic healthcare assets. The company emphasi", "url": "https://quartr.com/events/innoviva-inc-inva-goldman-sachs-47th-annual-global-healthcare-conference-2026_Feiu2h0S", "source_name": "Quartr", "published_at": "2026-06-09T19:09:28", "published_display": "09 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (INVA) and Scalable Risk", "summary": "This article analyzes Innoviva Inc. (NASDAQ: INVA), highlighting divergent sentiment across different time horizons, suggesting choppy market conditions. It identifies a mid-channel oscillation pattern and outlines three distinct AI-generated trading strategies\u2014Position Trading, ", "url": "https://news.stocktradersdaily.com/news_release/151/Understanding_the_Setup:_INVA_and_Scalable_Risk_060526020802_1780639682.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-05T02:08:00", "published_display": "05 Jun 2026 02:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva to Participate in Upcoming Investor Conferences", "summary": "Innoviva, Inc., a diversified biopharmaceutical company, announced its participation in two upcoming investor conferences in June 2026. Management will attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th and the BTIG Infectious Disease Day on June 16th. ", "url": "https://www.ncnewsonline.com/news/national/innoviva-to-participate-in-upcoming-investor-conferences/article_34e6400a-e200-57be-8478-7f37f9259ccf.html", "source_name": "New Castle News", "published_at": "2026-06-03T04:10:17", "published_display": "03 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Board Shift And New Treatment Launch Create Valuation Question", "summary": "Innoviva (NasdaqGS:INVA) has appointed Josephine Linden to its Board following two director resignations related to Syndeio BioSciences, a company Innoviva supports. Concurrently, Innoviva is preparing to launch a newly approved gonorrhea treatment. These developments, set agains", "url": "https://www.sahmcapital.com/news/content/innoviva-board-shift-and-new-treatment-launch-create-valuation-question-2026-05-31", "source_name": "Sahm", "published_at": "2026-06-02T14:38:48", "published_display": "02 Jun 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc. to Present at Investor Conferences", "summary": "Innoviva, Inc. announced its participation in upcoming investor conferences, where its management team will present business and strategic insights. These presentations offer a platform for Innoviva to discuss its financial performance, ongoing projects, and future outlook with b", "url": "https://www.geneonline.com/innoviva-inc-to-present-at-investor-conferences/", "source_name": "geneonline.com", "published_at": "2026-06-02T03:09:16", "published_display": "02 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $46", "summary": "HC Wainwright & Co. has reiterated a \"Buy\" rating for Innoviva (INVA), maintaining a price target of $46.00, despite the stock being 5.7% overvalued according to GuruFocus's GF Value\u2122. Innoviva, which operates in the biotechnology industry, has a strong GF Score\u2122 of 90/100, indic", "url": "https://www.gurufocus.com/news/8893279/inva-reiterated-by-hc-wainwright-co-price-target-maintained-at-46?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-01T12:39:57", "published_display": "01 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Innoviva Successfully Pivoted Beyond its Royalty Roots", "summary": "Innoviva (INVA) is successfully transforming from a royalty-dependent company into a diversified biopharmaceutical entity with a strong Q4 2025 earnings beat driven by its Specialty Therapeutics platform and robust sales of XacDuro in China. The company's strategic pivot includes", "url": "https://www.kavout.com/market-lens/has-innoviva-successfully-pivoted-beyond-its-royalty-roots", "source_name": "Kavout", "published_at": "2026-05-30T01:09:59", "published_display": "30 May 2026 01:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPODNtalByRm5SSlZpcXlYSzBDcHZteHFTZENTOGdLcFUxNElXNzlXQVcxQVhJbmRvWFlISThWUXpXZGVVQ3hDUkJqb0dBUzFiblFpc0tYRExyYWxGd2RkcWhFZ3FYZlVhT0xrNnhjcGlTSzRfOXlTNzdGbFd0cXNkZ0xtX2NYdUR6TlZTaFA5TUd2bTVkVDFwc0h3UGJCbFZpa2VqdTJZci12WDU5ekJBNnBQUFFjVlRFUWNuRHY1MW5sWlhINFppN2s2emsyVm95Y1FmVw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVA Reiterates by BTIG -- Price Target Maintained at $42", "summary": "BTIG analyst Julian Harrison has reiterated a \"Buy\" rating for Innoviva (INVA), maintaining a price target of $42.00, despite the stock currently trading at $22.46, indicating it is 10.9% overvalued according to GuruFocus's GF Value\u2122. Innoviva, a biopharmaceutical company with a ", "url": "https://www.gurufocus.com/news/8881928/inva-reiterates-by-btig-price-target-maintained-at-42?mobile=true", "source_name": "GuruFocus", "published_at": "2026-05-26T22:12:16", "published_display": "26 May 2026 22:12", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals", "summary": "Innoviva Inc (INVA) has been identified as a strong value stock due to its high fundamental ratings across valuation, profitability, health, and growth metrics. The company boasts a cheap valuation with a P/E of 6.01, robust profitability shown by a 119.88% profit margin, excelle", "url": "https://www.chartmill.com/news/INVA/Chartmill-48991-INNOVIVA-INC-NASDAQINVA-Scores-as-a-Value-Stock-with-Strong-Fundamentals", "source_name": "ChartMill", "published_at": "2026-05-25T10:38:45", "published_display": "25 May 2026 10:38", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (INVA) That Institutions Follow", "summary": "This article from Stock Traders Daily analyzes the technical signals for Innoviva Inc. (NASDAQ: INVA), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies resistance testing, an exceptional short setup with a 29.0:1 risk-reward ratio, and p", "url": "https://news.stocktradersdaily.com/news_release/8/The_Technical_Signals_Behind_INVA_That_Institutions_Follow_052526010002_1779685202.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-25T01:10:27", "published_display": "25 May 2026 01:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) CFO adds ESPP shares and uses stock to pay taxes", "summary": "Innoviva, Inc.'s CFO, Stephen Basso, engaged in routine equity activities, acquiring 1,123 shares through the company's Employee Stock Purchase Plan (ESPP) on May 15, 2026. Subsequently, on May 20, 2026, 559 shares were withheld to cover income taxes related to the vesting of pri", "url": "https://www.stocktitan.net/sec-filings/INVA/form-4-innoviva-inc-insider-trading-activity-96657c265d3c.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:19", "published_display": "22 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) CEO logs ESPP share grant and tax withholding on Form 4", "summary": "Innoviva, Inc. CEO Pavel Raifeld reported routine equity compensation activity through a Form 4 filing. On May 15, he acquired 1,123 shares of common stock at no cost via the Employee Stock Purchase Plan, and on May 20, 1,130 shares were withheld by Innoviva to cover income taxes", "url": "https://www.stocktitan.net/sec-filings/INVA/form-4-innoviva-inc-insider-trading-activity-7ba3c6339eea.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:19", "published_display": "22 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (NASDAQ: INVA) CAO has shares withheld to cover tax obligations", "summary": "Innoviva, Inc.'s Chief Accounting Officer, Marianne Zhen, had 1,127 shares of common stock withheld by the company to cover income tax obligations related to the quarterly vesting of prior equity grants. This transaction, executed on May 20, 2026, at $22.24 per share, was a tax-w", "url": "https://www.stocktitan.net/sec-filings/INVA/form-4-innoviva-inc-insider-trading-activity-8bbadbec167f.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:19", "published_display": "22 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Board Shakeup Puts Governance And Valuation In Focus", "summary": "Innoviva announced the resignation of two directors from its board, with Josephine Linden appointed as an independent director to the Audit Committee. This change puts corporate governance and valuation in focus, especially as the stock has seen significant long-term gains but re", "url": "https://www.sahmcapital.com/news/content/innoviva-board-shakeup-puts-governance-and-valuation-in-focus-2026-05-22", "source_name": "Sahm", "published_at": "2026-05-21T09:10:27", "published_display": "21 May 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) director receives RSU and stock option grants as board compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYTZPblRDRjJ5U2UxZVBLUUV6WFZUWDgzYzdpY25La21Obmx6bXVubjBwMWs1d1owQlZFOUNwRW1FMHRDN2xIZmlPRGZGMjVscm8tcVdPVTdyXzdETDN4NFJiZGVnbXVhcXJRTE1LaTdid0hHUlpGVFcxSll2WHktOGEzMFo4ck5EZmRjLVRvZXNuWFU2ZlA0ck1TcnJFTnB5ZWtDeXNZSU03UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQTXYzYVpUTzVnTFB0dlNxRktTbDdQYmN5blR1Z3hWdmd0NEVjLVdXTEUzM2JqZjdhSTZhd3hCNWZFdDl4OTg2ZENqQlBPWTV5NHN5RUtzU2VEQ3plWnJFUkptd3RaUE5OclJVVGhyTURvSFgtaW9vRVA4amlSMVg5UjJpclFLUnhnVlRtZUdlT2FQSkZSYTBrXzFfRWRwT0s3M1V1RQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQLWNCci1Bc0lXWmNiNWZ5MEdCZnZaRC1JWVNERFlNODRUeEowdzlUZ1BQUkFDR1dXRnV6SUhCU3Q5NG9PM3pWang0R0tKX2JvUnV1V1JDNXVXdkVOaE04SndCdHpSaEdEOUFNRXNLMXl2cDFsT1NhTWk2Z0Q0MkQyTF9HSnVzTlQ5cmQ4SkZBR3dpU2FFZm04U3dvZ1c?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/innoviva-q1-earnings-snapshot-214351342.html", "source_name": "Associated Press", "published_at": "2026-05-06T21:43:51+00:00", "published_display": "06 May 2026 21:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) Tops Q1 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQbTZGdWRlRDR1bHN5N09jQXo1SVc3RmtoakNBMGd2d3Q1NnVoNHc4emNJdEhEd0VDbGxXaG5OMmozTDVneTVHRHRvTnM4a0s3cXptb1E0eFU4cE14Nm9IMkltcngwMnlmZ1BxSk1DcGRJQXd3b19vM1NoaFNQSUFuSnlSWDA1U2NMZDZ0TlVNVjRselBfZ1ZkMmwyaTQ5THVJ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcE1LbU1wYlpXZlQ3STZXOFM4eDZxYWw1YzVJQkk4RzFORG82MEozRmdUYVUzQ3lYYThVM0huejNHckRfNXFGWEIyMkw0Y0dobUE5S1ZNOHpGSV8wd2tQSHJfXzRVTGlHMk1ORXhEazE5S0hWM2gyc3hDOVdfSnh0ci1uS05nWlk2bVU5c1JTd2QzcEk5Uk5DXzNZNVFHRGZkdDhBakpRWDBBOFdqcGF4YlJfZk1nVDN3Mnl6SFpSd0V2eWl6VWw2M1o3T0lEWElZcWtZMHV3MFZPcFBRN1E?oc=5", "source_name": "Business Wire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOQ3czZzJ6SEhYVXRZeUwzOXBmMzFIOE5vbjdRUHQ4aUdubDEwY0dsLUJiZ0NQZTJHSWM4eHZKNjJRYnVGODhLRTdZekRvZFFzYzdKRHFjS0hWRDZueG45SnJIYXhPUjVMajhoN1M2NFo1MExNUko1MzU1ckV3d2tFSldpaEpjSnE5WktIaTR0UENycGJnTnVGMFRVV2tyOWM?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Innoviva (INVA) After Its Strong Multi Year Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOczJNUVJjbTJiNjlWTWp5ZXBtWURoQ3RnS1RjbFBuR2tVa1BGQ2tYU1lwWjhOZUExQ3Y1TF9UUlRQNUxyZV9Id18tQXk0SUl0QzFJSk1pbjRZUUhqU0JMOE56Nkd2dDcyQ2N1ZF9JUjlYN1RTUWJzcS1Sa09Bd3loVjBYVElGSEE?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc. (INVA): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9mZi1JRjFaY2NJMS1iTkNzOVBTOVRiNkxUekNoQWZRSTM1YWJWRHlfZnBFMnhfSWRHU0NxTGNJSVk0YTBITkZzZUh4NENiWlFXR0FmeERZYWxzQm1hRkZPYXV2X0JGN0VCdUMxQ2EzaVJxQnhickFGYXQtNjFwZw?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Innoviva's oral antibiotic for gonorrhea", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQOWVQSERxNVdqOU1TZkMyTVdBUkphOWplMmFsTGUtSTcxMl9tQW1LYUdMYWlkSXFyaEdDQU56c1JWeXpoQ1dmb2dyandHYmxxVTJxNFdhWjVNWFhSUTZwb19hcldEQU5fbnZMdzhMMk9Fd2o0QzJYTndtd21iWlJtaWNRcXJlRW5uZlhhanFhZmNqR0t2MEF6SlVKcXhoVkllSVU2MmxFLW84RlFpbmUyY3hsUUZVcEgwN1hHVnF1T2k2dnd4Zmlfcnlta29jMVg5NkE3SENtUDVZZ1JCQkF4Mks2MlVZakU?oc=5", "source_name": "Reuters", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Innoviva's (NASDAQ:INVA) Solid Profits Have Weak Fundamentals", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc.'s (NASDAQ:INVA) Shares Bounce 26% But Its Business Still Trails The Market", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNcHJ0azQ4LUlOXzdiRW1zSTR2MGRmUXRET0Q2UkM3RkZDYXprWW1LRE5OUXVWdVJIbDdIV0d4UFdSOTV5RGhtU1ZFcnp2WkNHOXM3ZWM3T1IxVzUwUGs0dUxMNkgyV3BMT2RtbVNTXzNpc1VGTERVdTVSM0kwRTFWX2pvZUNrRGt2ZjV1Y29WU3VPWjVLVzVUV1dDQkVYNXUzbWhBWVBudmVhdTFpNU5nQzVsRS1Bem5zTnZvRkF2Z3Z2NzVkd1JV?oc=5", "source_name": "BioSpace", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Innoviva, Inc. Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE45b1lub19JR09uY3JuOE1ET296SlB1b052TGx6a0RxSmJNRndfdFFCcHVaS2FucTZDRG5ldnU2NXh2dllTbU53NEwzaE0wd1RucjVCeWVpZXUtWURxMXpnRUpybw?oc=5", "source_name": "TradingView", "published_at": "2025-08-09T09:13:33+00:00", "published_display": "09 Aug 2025 09:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-09T07:00:00+00:00", "published_display": "09 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Innoviva stock trades down to $22.49 as Western Thoracic conference focus draws attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOemJlbV9MU2JvblA5YUFWWGVoSnpPWXJOZGhtUWI0ZDlMQTJRVEhHSHRUb3lJWElUcnZxTm9LZkpFSlE4Tm1DOS1YdHRsY1FSYTAzaW5TYzJIVUFxeGNTQVZ6SGhfM0lybERUcXRCSk1UNGpZYmJhZy02RjVFTUI3X2xSX3hmZURuRGU2Wm1UQmhmY1R3UDIwdg?oc=5", "source_name": "Traders Union", "published_at": "2026-06-22T11:28:08+00:00", "published_display": "22 Jun 2026 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) Stock Could Be 61% Below Fair Value After XACDURO Deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-20T23:41:38+00:00", "published_display": "20 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will XACDURO Licensing Deal With Dr. Reddy\u2019s Reshape Innoviva\u2019s (INVA) Infectious Disease Strategy?", "summary": "Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., recently entered an exclusive distribution and licensing agreement with Dr. Reddy\u2019s Laboratories for XACDURO\u00ae across various international regions. This deal helps expand XACDURO\u00ae's global reach and offers Innoviva ", "url": "https://www.sahmcapital.com/news/content/will-xacduro-licensing-deal-with-dr-reddys-reshape-innovivas-inva-infectious-disease-strategy-2026-06-19", "source_name": "Sahm", "published_at": "2026-06-19T21:09:36", "published_display": "19 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nortiva Bio Launches to Develop Long-Acting Oral Medicines", "summary": "Nortiva Bio, a clinical-stage biopharmaceutical company and wholly-owned subsidiary of Innoviva, Inc., has officially launched to develop long-acting oral medicines. The company utilizes its proprietary LYNX\u2122 drug delivery platform, which can transform daily pills into once-month", "url": "https://www.businesswire.com/news/home/20260618487727/en/Nortiva-Bio-Launches-to-Develop-Long-Acting-Oral-Medicines", "source_name": "Business Wire", "published_at": "2026-06-19T08:39:18", "published_display": "19 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Innoviva Inc (INVA), detailing its current earnings forecast score, average price target from analysts, and a breakdown of analyst ratings. It also includes expected revenue for the next quarter, past and future EPS performance, and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T21:09:36", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva spins out Nortiva Bio to make pills last up to a month", "summary": "Innoviva, Inc. has officially launched Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines using its proprietary LYNX\u2122 drug delivery platform. This platform aims to transform daily pills into single-dose therapies lasting up to", "url": "https://www.stocktitan.net/news/INVA/nortiva-bio-launches-to-develop-long-acting-oral-7zyvymcas4kb.html", "source_name": "Stock Titan", "published_at": "2026-06-18T11:40:13", "published_display": "18 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Innoviva Inc (INVA) demonstrates robust financial health, ranking 22nd out of 157 in the Pharmaceuticals industry with a financial score of 8.98. The company reported a 10.56% year-over-year increase in quarterly revenue to $97.99 million and a significant 500.56% year-over-year ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:18", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE5hZkI4ZmFsWXFaWFFUSVlIalJ4Zy1UV0thRERxQU5ZTi1RY0o3dVllcmFGUHAzUlBobTVtZGtWemJUblc2d0lqeWIzaEd3MkJrY0tVWk9yTERaaTVkWmdVYlljOXd0bzd1UW9sQ0k3WWhPTHZJdVdV?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:53:36+00:00", "published_display": "17 Jun 2026 21:53", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE0yWUdDMGNXaTNkeXgtQkttajlRNlF3eExmbUZ1MkFYMHR0bzkxNE9FanNxNHZvY2lPbzNkcFUwb1hXZmFEVUxpM3paZWZTcmVMZXdkd0dyamxYVHVIRkVMWWVJUGs5elE1bThDeUxHaTQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T21:47:04+00:00", "published_display": "17 Jun 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Innoviva Inc (INVA), focusing on business segments and regional contributions. It notes that relevant data for recent fiscal quarters (FY2025Q1, Q2, Q4) and FY2024 has not yet been disclosed by the company. However, it does show a Uni", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:04", "published_display": "17 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Innoviva Inc's (INVA) historical dividend payouts and stock splits. It states that no dividend data is available for the past five years and no stock split data is found. The article also includes current stock performance metrics for INVA.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T18:40:03", "published_display": "17 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Inc (INVA) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Innoviva Inc (INVA), listing its major shareholders and their respective proportions. It also categorizes shareholders by type, such as investment advisors and hedge funds, and provides a historical overview of institutional share", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-inva/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T18:11:03", "published_display": "17 Jun 2026 18:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Specialty Therapeutics inks distribution and licensing agreement with Dr. Reddy\u2019s", "summary": "Innoviva Specialty Therapeutics has partnered with Dr. Reddy\u2019s Laboratories through an exclusive distribution and licensing agreement. This collaboration aims to develop and commercialize XACDURO\u00ae for the treatment of severe Acinetobacter baumannii-calcoaceticus complex infection", "url": "https://www.biospectrumindia.com/news/16/27981/innoviva-specialty-therapeutics-inks-distribution-and-licensing-agreement-with-dr-reddys-.html", "source_name": "BioSpectrum India", "published_at": "2026-06-17T11:11:03", "published_display": "17 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy\u2019s for XACDURO", "summary": "Innoviva Specialty Therapeutics has partnered with Dr. Reddy\u2019s Laboratories for the distribution and licensing of XACDURO in select international markets including South and Central America, the Caribbean, Russia, and CIS countries. This agreement aims to expand access to XACDURO", "url": "https://www.businesswire.com/news/home/20260616536715/en/Innoviva-Specialty-Therapeutics-Announces-Distribution-and-Licensing-Agreement-with-Dr.-Reddys-for-XACDURO-in-Select-International-Markets", "source_name": "Business Wire", "published_at": "2026-06-17T08:39:18", "published_display": "17 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy\u2019s for XACDURO\u00ae in Select International Markets", "summary": "Innoviva Specialty Therapeutics has partnered with Dr. Reddy's Laboratories to distribute and commercialize the pneumonia drug XACDURO in Latin America, the Caribbean, Russia, and CIS countries. This agreement aims to expand access to XACDURO, an antibiotic for hospital-acquired ", "url": "https://www.stocktitan.net/news/INVA/innoviva-specialty-therapeutics-announces-distribution-and-licensing-uqmj82r0xass.html", "source_name": "Stock Titan", "published_at": "2026-06-17T07:40:03", "published_display": "17 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva unit signs distribution deal with Dr. Reddy\u2019s By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQanIxYU9LdUNTREZQSHc4U2VxTXN3TndpelFScDZWRF9oX3hhVXk3RFF4Yy1nc08zQmdRWm9yOWZ0dFNLVXpXQVlRN1VHNU44bkRPMTFNUmZHQUd6d1FnUlgyVUItMjZ5WGs3QWlraU1GQXpCdDgxNEQ5Vzc1RmljeFBPVHR3TUVYd1FDaW5WSW0zZTZHZllRbVRSbGZJbmV5TW1fS3FjV1dRY1JvVlhXcmZBWQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T14:08:00+00:00", "published_display": "16 Jun 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva partners with Dr. Reddy's for XACDURO licensing", "summary": "Innoviva Specialty Therapeutics has entered an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for its antibiotic XACDURO. Dr. Reddy's will handle the development and commercialization of the drug in South America, Central America, the Caribbean, and ", "url": "https://grafa.com/en/news/united-states/innoviva-dr-reddys-xacduro-licensing-agreement", "source_name": "grafa.com", "published_at": "2026-06-16T14:09:28", "published_display": "16 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva' Specialty Therapeutics Unit Signs Licensing Deal With Dr. Reddy's for Xacduro", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/innoviva-apos-specialty-therapeutics-unit-122119947.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:21:19+00:00", "published_display": "16 Jun 2026 12:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva unit signs distribution deal with Dr. Reddy\u2019s", "summary": "Innoviva Specialty Therapeutics has signed an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd. for its antibiotic XACDURO in South and Central America, the Caribbean, Russia, and CIS countries. Innoviva Inc. (NASDAQ:INVA) is set to receive an upfr", "url": "https://m.uk.investing.com/news/stock-market-news/innoviva-unit-signs-distribution-deal-with-dr-reddys-93CH-4730598?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-16T13:10:29", "published_display": "16 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the INVA Inflection", "summary": "This article analyzes Innoviva Inc. (NASDAQ: INVA) with a neutral near and mid-term outlook but a positive long-term bias. It highlights a strong risk-reward short setup and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, eac", "url": "https://news.stocktradersdaily.com/news_release/149/Responsive_Playbooks_and_the_INVA_Inflection_061626033802_1781595482.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-16T03:38:00", "published_display": "16 Jun 2026 03:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary", "summary": "Innoviva (INVA) presented at the 47th Annual Goldman Sachs Global Healthcare Conference, highlighting its diversified business model comprising resilient royalty streams, a rapidly growing specialty therapeutics business (IST), and strategic healthcare assets. The company emphasi", "url": "https://quartr.com/events/innoviva-inc-inva-goldman-sachs-47th-annual-global-healthcare-conference-2026_Feiu2h0S", "source_name": "Quartr", "published_at": "2026-06-09T19:09:28", "published_display": "09 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (INVA) and Scalable Risk", "summary": "This article analyzes Innoviva Inc. (NASDAQ: INVA), highlighting divergent sentiment across different time horizons, suggesting choppy market conditions. It identifies a mid-channel oscillation pattern and outlines three distinct AI-generated trading strategies\u2014Position Trading, ", "url": "https://news.stocktradersdaily.com/news_release/151/Understanding_the_Setup:_INVA_and_Scalable_Risk_060526020802_1780639682.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-05T02:08:00", "published_display": "05 Jun 2026 02:08", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva to Participate in Upcoming Investor Conferences", "summary": "Innoviva, Inc., a diversified biopharmaceutical company, announced its participation in two upcoming investor conferences in June 2026. Management will attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th and the BTIG Infectious Disease Day on June 16th. ", "url": "https://www.ncnewsonline.com/news/national/innoviva-to-participate-in-upcoming-investor-conferences/article_34e6400a-e200-57be-8478-7f37f9259ccf.html", "source_name": "New Castle News", "published_at": "2026-06-03T04:10:17", "published_display": "03 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Board Shift And New Treatment Launch Create Valuation Question", "summary": "Innoviva (NasdaqGS:INVA) has appointed Josephine Linden to its Board following two director resignations related to Syndeio BioSciences, a company Innoviva supports. Concurrently, Innoviva is preparing to launch a newly approved gonorrhea treatment. These developments, set agains", "url": "https://www.sahmcapital.com/news/content/innoviva-board-shift-and-new-treatment-launch-create-valuation-question-2026-05-31", "source_name": "Sahm", "published_at": "2026-06-02T14:38:48", "published_display": "02 Jun 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc. to Present at Investor Conferences", "summary": "Innoviva, Inc. announced its participation in upcoming investor conferences, where its management team will present business and strategic insights. These presentations offer a platform for Innoviva to discuss its financial performance, ongoing projects, and future outlook with b", "url": "https://www.geneonline.com/innoviva-inc-to-present-at-investor-conferences/", "source_name": "geneonline.com", "published_at": "2026-06-02T03:09:16", "published_display": "02 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $46", "summary": "HC Wainwright & Co. has reiterated a \"Buy\" rating for Innoviva (INVA), maintaining a price target of $46.00, despite the stock being 5.7% overvalued according to GuruFocus's GF Value\u2122. Innoviva, which operates in the biotechnology industry, has a strong GF Score\u2122 of 90/100, indic", "url": "https://www.gurufocus.com/news/8893279/inva-reiterated-by-hc-wainwright-co-price-target-maintained-at-46?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-01T12:39:57", "published_display": "01 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Innoviva Successfully Pivoted Beyond its Royalty Roots", "summary": "Innoviva (INVA) is successfully transforming from a royalty-dependent company into a diversified biopharmaceutical entity with a strong Q4 2025 earnings beat driven by its Specialty Therapeutics platform and robust sales of XacDuro in China. The company's strategic pivot includes", "url": "https://www.kavout.com/market-lens/has-innoviva-successfully-pivoted-beyond-its-royalty-roots", "source_name": "Kavout", "published_at": "2026-05-30T01:09:59", "published_display": "30 May 2026 01:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPODNtalByRm5SSlZpcXlYSzBDcHZteHFTZENTOGdLcFUxNElXNzlXQVcxQVhJbmRvWFlISThWUXpXZGVVQ3hDUkJqb0dBUzFiblFpc0tYRExyYWxGd2RkcWhFZ3FYZlVhT0xrNnhjcGlTSzRfOXlTNzdGbFd0cXNkZ0xtX2NYdUR6TlZTaFA5TUd2bTVkVDFwc0h3UGJCbFZpa2VqdTJZci12WDU5ekJBNnBQUFFjVlRFUWNuRHY1MW5sWlhINFppN2s2emsyVm95Y1FmVw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVA Reiterates by BTIG -- Price Target Maintained at $42", "summary": "BTIG analyst Julian Harrison has reiterated a \"Buy\" rating for Innoviva (INVA), maintaining a price target of $42.00, despite the stock currently trading at $22.46, indicating it is 10.9% overvalued according to GuruFocus's GF Value\u2122. Innoviva, a biopharmaceutical company with a ", "url": "https://www.gurufocus.com/news/8881928/inva-reiterates-by-btig-price-target-maintained-at-42?mobile=true", "source_name": "GuruFocus", "published_at": "2026-05-26T22:12:16", "published_display": "26 May 2026 22:12", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals", "summary": "Innoviva Inc (INVA) has been identified as a strong value stock due to its high fundamental ratings across valuation, profitability, health, and growth metrics. The company boasts a cheap valuation with a P/E of 6.01, robust profitability shown by a 119.88% profit margin, excelle", "url": "https://www.chartmill.com/news/INVA/Chartmill-48991-INNOVIVA-INC-NASDAQINVA-Scores-as-a-Value-Stock-with-Strong-Fundamentals", "source_name": "ChartMill", "published_at": "2026-05-25T10:38:45", "published_display": "25 May 2026 10:38", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (INVA) That Institutions Follow", "summary": "This article from Stock Traders Daily analyzes the technical signals for Innoviva Inc. (NASDAQ: INVA), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies resistance testing, an exceptional short setup with a 29.0:1 risk-reward ratio, and p", "url": "https://news.stocktradersdaily.com/news_release/8/The_Technical_Signals_Behind_INVA_That_Institutions_Follow_052526010002_1779685202.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-25T01:10:27", "published_display": "25 May 2026 01:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) CFO adds ESPP shares and uses stock to pay taxes", "summary": "Innoviva, Inc.'s CFO, Stephen Basso, engaged in routine equity activities, acquiring 1,123 shares through the company's Employee Stock Purchase Plan (ESPP) on May 15, 2026. Subsequently, on May 20, 2026, 559 shares were withheld to cover income taxes related to the vesting of pri", "url": "https://www.stocktitan.net/sec-filings/INVA/form-4-innoviva-inc-insider-trading-activity-96657c265d3c.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:19", "published_display": "22 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) CEO logs ESPP share grant and tax withholding on Form 4", "summary": "Innoviva, Inc. CEO Pavel Raifeld reported routine equity compensation activity through a Form 4 filing. On May 15, he acquired 1,123 shares of common stock at no cost via the Employee Stock Purchase Plan, and on May 20, 1,130 shares were withheld by Innoviva to cover income taxes", "url": "https://www.stocktitan.net/sec-filings/INVA/form-4-innoviva-inc-insider-trading-activity-7ba3c6339eea.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:19", "published_display": "22 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (NASDAQ: INVA) CAO has shares withheld to cover tax obligations", "summary": "Innoviva, Inc.'s Chief Accounting Officer, Marianne Zhen, had 1,127 shares of common stock withheld by the company to cover income tax obligations related to the quarterly vesting of prior equity grants. This transaction, executed on May 20, 2026, at $22.24 per share, was a tax-w", "url": "https://www.stocktitan.net/sec-filings/INVA/form-4-innoviva-inc-insider-trading-activity-8bbadbec167f.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:19", "published_display": "22 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Board Shakeup Puts Governance And Valuation In Focus", "summary": "Innoviva announced the resignation of two directors from its board, with Josephine Linden appointed as an independent director to the Audit Committee. This change puts corporate governance and valuation in focus, especially as the stock has seen significant long-term gains but re", "url": "https://www.sahmcapital.com/news/content/innoviva-board-shakeup-puts-governance-and-valuation-in-focus-2026-05-22", "source_name": "Sahm", "published_at": "2026-05-21T09:10:27", "published_display": "21 May 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) director receives RSU and stock option grants as board compensation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYTZPblRDRjJ5U2UxZVBLUUV6WFZUWDgzYzdpY25La21Obmx6bXVubjBwMWs1d1owQlZFOUNwRW1FMHRDN2xIZmlPRGZGMjVscm8tcVdPVTdyXzdETDN4NFJiZGVnbXVhcXJRTE1LaTdid0hHUlpGVFcxSll2WHktOGEzMFo4ck5EZmRjLVRvZXNuWFU2ZlA0ck1TcnJFTnB5ZWtDeXNZSU03UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQTXYzYVpUTzVnTFB0dlNxRktTbDdQYmN5blR1Z3hWdmd0NEVjLVdXTEUzM2JqZjdhSTZhd3hCNWZFdDl4OTg2ZENqQlBPWTV5NHN5RUtzU2VEQ3plWnJFUkptd3RaUE5OclJVVGhyTURvSFgtaW9vRVA4amlSMVg5UjJpclFLUnhnVlRtZUdlT2FQSkZSYTBrXzFfRWRwT0s3M1V1RQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQLWNCci1Bc0lXWmNiNWZ5MEdCZnZaRC1JWVNERFlNODRUeEowdzlUZ1BQUkFDR1dXRnV6SUhCU3Q5NG9PM3pWang0R0tKX2JvUnV1V1JDNXVXdkVOaE04SndCdHpSaEdEOUFNRXNLMXl2cDFsT1NhTWk2Z0Q0MkQyTF9HSnVzTlQ5cmQ4SkZBR3dpU2FFZm04U3dvZ1c?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/innoviva-q1-earnings-snapshot-214351342.html", "source_name": "Associated Press", "published_at": "2026-05-06T21:43:51+00:00", "published_display": "06 May 2026 21:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva (INVA) Tops Q1 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQbTZGdWRlRDR1bHN5N09jQXo1SVc3RmtoakNBMGd2d3Q1NnVoNHc4emNJdEhEd0VDbGxXaG5OMmozTDVneTVHRHRvTnM4a0s3cXptb1E0eFU4cE14Nm9IMkltcngwMnlmZ1BxSk1DcGRJQXd3b19vM1NoaFNQSUFuSnlSWDA1U2NMZDZ0TlVNVjRselBfZ1ZkMmwyaTQ5THVJ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcE1LbU1wYlpXZlQ3STZXOFM4eDZxYWw1YzVJQkk4RzFORG82MEozRmdUYVUzQ3lYYThVM0huejNHckRfNXFGWEIyMkw0Y0dobUE5S1ZNOHpGSV8wd2tQSHJfXzRVTGlHMk1ORXhEazE5S0hWM2gyc3hDOVdfSnh0ci1uS05nWlk2bVU5c1JTd2QzcEk5Uk5DXzNZNVFHRGZkdDhBakpRWDBBOFdqcGF4YlJfZk1nVDN3Mnl6SFpSd0V2eWl6VWw2M1o3T0lEWElZcWtZMHV3MFZPcFBRN1E?oc=5", "source_name": "Business Wire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOQ3czZzJ6SEhYVXRZeUwzOXBmMzFIOE5vbjdRUHQ4aUdubDEwY0dsLUJiZ0NQZTJHSWM4eHZKNjJRYnVGODhLRTdZekRvZFFzYzdKRHFjS0hWRDZueG45SnJIYXhPUjVMajhoN1M2NFo1MExNUko1MzU1ckV3d2tFSldpaEpjSnE5WktIaTR0UENycGJnTnVGMFRVV2tyOWM?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Innoviva (INVA) After Its Strong Multi Year Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxOczJNUVJjbTJiNjlWTWp5ZXBtWURoQ3RnS1RjbFBuR2tVa1BGQ2tYU1lwWjhOZUExQ3Y1TF9UUlRQNUxyZV9Id18tQXk0SUl0QzFJSk1pbjRZUUhqU0JMOE56Nkd2dDcyQ2N1ZF9JUjlYN1RTUWJzcS1Sa09Bd3loVjBYVElGSEE?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc. (INVA): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9mZi1JRjFaY2NJMS1iTkNzOVBTOVRiNkxUekNoQWZRSTM1YWJWRHlfZnBFMnhfSWRHU0NxTGNJSVk0YTBITkZzZUh4NENiWlFXR0FmeERZYWxzQm1hRkZPYXV2X0JGN0VCdUMxQ2EzaVJxQnhickFGYXQtNjFwZw?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Innoviva's oral antibiotic for gonorrhea", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQOWVQSERxNVdqOU1TZkMyTVdBUkphOWplMmFsTGUtSTcxMl9tQW1LYUdMYWlkSXFyaEdDQU56c1JWeXpoQ1dmb2dyandHYmxxVTJxNFdhWjVNWFhSUTZwb19hcldEQU5fbnZMdzhMMk9Fd2o0QzJYTndtd21iWlJtaWNRcXJlRW5uZlhhanFhZmNqR0t2MEF6SlVKcXhoVkllSVU2MmxFLW84RlFpbmUyY3hsUUZVcEgwN1hHVnF1T2k2dnd4Zmlfcnlta29jMVg5NkE3SENtUDVZZ1JCQkF4Mks2MlVZakU?oc=5", "source_name": "Reuters", "published_at": "2025-12-12T08:00:00+00:00", "published_display": "12 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva's (NASDAQ:INVA) Solid Profits Have Weak Fundamentals", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc.'s (NASDAQ:INVA) Shares Bounce 26% But Its Business Still Trails The Market", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNcHJ0azQ4LUlOXzdiRW1zSTR2MGRmUXRET0Q2UkM3RkZDYXprWW1LRE5OUXVWdVJIbDdIV0d4UFdSOTV5RGhtU1ZFcnp2WkNHOXM3ZWM3T1IxVzUwUGs0dUxMNkgyV3BMT2RtbVNTXzNpc1VGTERVdTVSM0kwRTFWX2pvZUNrRGt2ZjV1Y29WU3VPWjVLVzVUV1dDQkVYNXUzbWhBWVBudmVhdTFpNU5nQzVsRS1Bem5zTnZvRkF2Z3Z2NzVkd1JV?oc=5", "source_name": "BioSpace", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Innoviva, Inc. Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTE45b1lub19JR09uY3JuOE1ET296SlB1b052TGx6a0RxSmJNRndfdFFCcHVaS2FucTZDRG5ldnU2NXh2dllTbU53NEwzaE0wd1RucjVCeWVpZXUtWURxMXpnRUpybw?oc=5", "source_name": "TradingView", "published_at": "2025-08-09T09:13:33+00:00", "published_display": "09 Aug 2025 09:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innoviva, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-09T07:00:00+00:00", "published_display": "09 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 58, "sentiment_summary": {"positive": 21, "negative": 4, "neutral": 33, "score": 56, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.29, "count": 18}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 22.49, "latest_week": "2026-06-19", "one_week_move": -1.1, "four_week_move": 0.1, "twelve_week_move": -0.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.558272, "market_dynamics_buy_signal": false, "relative_strength": -10.293949, "fair_value_gap": 25.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.4047, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.1% over one week, +0.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "simplywall.st", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "Sahm", "count": 3}, {"label": "Business Wire", "count": 3}, {"label": "Stock Traders Daily", "count": 3}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 18}, {"label": "Deals and strategy", "count": 5}, {"label": "Guidance", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.1% over one week, +0.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Innoviva stock trades down to $22.49 as Western Thoracic conference focus draws attention"}], "updated_at": "2026-06-23T00:08:54.066705+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}